… ProQR Announces Clearance of IND to Start Clinical Trial of … & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel A. de Boer, Chief Executive Officer of ProQR. “QR-421a has shown promising activity in both the …
Reported rapid, significant and durable improvements in vision at twelve months
Concordant improvement in key secondary outcome measures
The target registration dose of sepofarsen was well-tolerated with a favorable benefit/risk profile
Strengthens confidence
… ProQR Announces Japanese Axiomer™ Patent Upheld Following … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … 2023 with the Japanese Patent Office by a strawman against ProQR’s granted patent JP 7244922 , which is related to the …
… ProQR to Present its Axiomer® RNA Editing Technology at the … & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … USA, that is being held May 9-12, 2022 in Boston, MA, U.S. ProQR presentation Presentation title: Development of RNA …
… ProQR Announces Top-Line Results from Phase 2/3 Illuminate … Daniel A. de Boer, Founder and CEO of ProQR Therapeutics. “ProQR was founded with the goal of developing RNA therapies … many are feeling in the community,” said Benjamin R. Yerxa, Chief Executive Officer at the Foundation Fighting …